Drugs / aNK for Infusion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03136406 | Aug → Nov 2017 | malignant pancreatic neoplasm | ImmunityBio, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aNK for Infusion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03136406 ↗ |
| Modality | Cell therapy | “NK-92 cells” NCT03136406 ↗ |